Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

<p>Abstract</p> <p>Background</p> <p>The median age of newly diagnosed patients with non-small cell lung cancer (NSCLC) is 67 years, and one-third of patients are older than 75 years. Elderly patients are more vulnerable to the adverse effects of chemotherapy, and targe...

Full description

Bibliographic Details
Main Authors: Christos Chouaid, Hervé Le, Chrystelle Locher, Cecile Dujon, Pascal Thomas, Jean Bernard Auliac, Isabelle Monnet, Alain Vergnenegre
Format: Article
Language:English
Published: BMC 2012-07-01
Series:BMC Cancer
Subjects:
Cost-utility
Erlotinib
Non-small cell lung cancer
Elderly patients
Phase II trial
Online Access:http://www.biomedcentral.com/1471-2407/12/301

Internet

http://www.biomedcentral.com/1471-2407/12/301

Similar Items